Synthesis of novel thiazolidine-4-one derivatives and their anticancer activity
作者:Nosrat O Mahmoodi、Masoud Mohammadi Zeydi、Esmaeil Biazar、Zahra Kazeminejad
DOI:10.1080/10426507.2016.1239197
日期:2017.3.4
GRAPHICAL ABSTRACT ABSTRACT This paper describes the synthesis of a novel series of 1,3-thiazolidine-4-ones 6a-n by cycloaddition reaction of N-aryl-N'-acyl thioureas 4a-k with acetylenic esters 5a-b under microwave irradiation and solvent free conditions. Our method, compared to conventional heating conditions has the benefit of higher reaction yield and shorter reaction times. Structural confirmation
Structural and spectral studies of N-(4-chloro)benzoyl-N′-2-tolylthiourea
作者:Zhou Weiqun、Leng Kuisheng、Zhang Yong、Lude Lu
DOI:10.1016/s0022-2860(03)00371-5
日期:2003.9
The crystal and molecular structure of N-(4-chloro)benzoyl-N'-2-tolylthiourea (C(15)H(13)N(2)OSCl, M(r) = 304.79) is determined by X-ray diffraction. The crystal structure is monoclinic, space group P2(1)/n with a = 3.9898(3), b = 22.922(2), c = 16.005(2) Angstrom, beta = 104.367(4)degrees, V = 104.367(4) Angstrom(3), Z = 4, D(c) = 1.428 g/cm(3). The results of extended MO calculations using density functional theory (DFT) with a hybrid B3LYP density functional approximation and FTIR and NMR studies on the title compound are reported. With the basis sets of the 6-311G* quality, the DFT calculated bond parameters, harmonic vibrations and chemical shifts are in a very good agreement with experimental data. The intramolecular and intermolecular hydrogen bonds are discussed. Non-linear optical properties of the molecule are predicted. (C) 2003 Elsevier B.V. All rights reserved.
Pharmaceutical Compositions For and Methods of Inhibiting Hcv
申请人:Huang Mingjun
公开号:US20080207760A1
公开(公告)日:2008-08-28
The present invention relates generally to replicase complex defect inducers and pharmaceutical compositions containing such inducers. Methods of developing mutants that are resistant to replicase complex defect inducers are also provided. Further included are mutants that can be used in screening for replicase complex defect inducers. Methods of screening test compounds for the ability to induce the formation of replicase complex defects are also described. Also included are methods of inhibition of HCV replication by replicase complex defect inducers.